current treatment of hiv infection
Clicks: 259
ID: 145546
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
259 views
34 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #2 of 2 articles by views in jurnal ekonomi dan bisnis
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
With current antiretroviral therapy options, eradication of human immunodeficiency virus (HIV) is not possible, yet. For this reason many patients have to face lifelong treatment. Several epidemiological studies suggest a normal life expectancy for HIV-infected patients with a regular and continuous treatment. The success of treatment can be evaluated by virologic, immunologic and clinical parameters. Viral load is the most important indicator of response to treatment. Today, especially in therapy-naive patients without pre-existing mutations, the risk of treatment failure is very low. All current initial regimens consist of two nucleoside analogues combined with an integrase inhibitor, a boosted protease inhibitor, or nonnucleoside reverse-transcriptase inhibitor. In this review, treatment of HIV infection is summarized in the light of current guidelines.
| Reference Key |
kurtaran2015mediterraneancurrent
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Behice KURTARAN |
| Journal | jurnal ekonomi dan bisnis |
| Year | 2015 |
| DOI |
10.4274/mjima.2015.11
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.